A Registry Study on Biomarkers of Takayasu’s Arteritis (ARSBTA)

Learn more about:
Related Clinical Trial
Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis Comparison of Tofacitinib and Methotrexate in Takayasu’s Arteritis A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis A Pilot Study in Severe Patients With Takayasu Arteritis. Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients Drug-coated Balloon for Takayasu Arteritis Associated Renal Artery Stenosis The Registry Study of Takayasu Arteritis in East China Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases A Registry Study on Biomarkers of Takayasu’s Arteritis (ARSBTA) Infliximab Biosimilar in Takayasu’s Arteritis Exercise in Juvenile Takayasu Disease Pulmonary Artery Involvement in Takayasu’s Arteritis Anti-inflammatory Treatment for Inactive Takayasu Arteritis Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis Aerobic Capacity and Strength Exercise in Takayasu’s Arteritis Use of MRI and PET for Assessing Disease Activity in Takayasu’s Arteritis Impact and Utility of PET Versus Clinical Score for the Assessment of Inflammatory Activity in Takayasu Arteritis Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu’s Arteritis Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis Registration Study of Takayasu’s Arteritis in China Determining Disease Activity Biomarkers in Individuals With Takayasu’s Arteritis Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging China Takayasu Arteritis Registry (CTA Registry) Takayasu Arteritis Clinical Trial in China

Brief Title

A Registry Study on Biomarkers of Takayasu's Arteritis (ARSBTA)

Official Title

A Registry Study on Biomarkers of Takayasu's Arteritis

Brief Summary

      Takayasu arteritis is a chronic vasculitis mainly involving the aorta and its main branches
      such as the brachiocephalic, carotid, subclavian, vertebral, and renal arteries, as well as
      the coronary and pulmonary arteries. Inflammation causes segments of the vessels to become
      narrowed, blocked, or even stretched, possibly resulting in aneurysms. The disease is very
      rare but most commonly occurs in young Asian women. However, there is a considerable lack of
      understanding of the disease mechanism of Takayasu arteritis. Initially, the disease remains
      clinically silent (or remains undetected) until the patients present with vascular occlusion.
      Additionally, many individuals with Takayasu arteritis, however, have no apparent symptoms
      despite disease activity. Therefore, biomarkers for diagnosis and monitor disease activity in
      individuals with Takayasu arteritis are needed. In this study, the investigators therefore to
      use different methods to identify new biomarkers for diagnosing or monitoring the disease
      activity in individuals with Takayasu arteritis. These biomarkers may provide valuable
      insights into the underlying biochemical processes and aid the understanding of the
      pathophysiology of this disease.

Study Type


Primary Outcome

Diagnosis of each participant


Takayasu's Arteritis

Study Arms / Comparison Groups



* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

January 2016

Completion Date

December 2026

Primary Completion Date

December 2026

Eligibility Criteria


        Inclusion Criteria:

        Subjects who met the American College of Rheumatology 1990 classification criteria for
        Takayasu arteritis:

          1. Age of onset ≤40 years,

          2. Claudication of upper or lower extremities,

          3. Decreased pulsation of 1 or both brachial arteries,

          4. Difference of ≥ 10 mmHg in systolic blood pressure between arms,

          5. Bruit over subclavian arteries or aorta,

          6. *Arteriographic evidence showing a branch of the aorta stenosis or occlusion.

        Meeting more than 3 of 6 criteria suggests the diagnosis of Takayasu arteritis.

        *Angiography in this study was replaced by vascular magnetic resonance angiography(MRA)or
        computed tomography angiography(CTA).

        Exclusion Criteria:

          1. Arteriographic lesions that could be entirely due to atherosclerosis,

          2. Suffer from other autoimmune diseases (eg, ANCA-associated vasculitis, systemic lupus
             erythematosus, etc.) besides Takayasu arteritis,

          3. Cogan's syndrome,

          4. Behcet's disease,

          5. Subjects with any serious acute or chronic infection,

          6. Giant cell arteritis (large vessel vasculitis and at least 50 years old) or other
             infectious forms of large vessel vasculitis.


        Inclusion Criteria:

        Subjects with initial suspicion of having Takayasu arteritis or patients with Takayasu
        arteritis need assessment of disease activity were prospectively enrolled.

        Exclusion Criteria:

          1. Patients without image studies.

          2. Patients with confirmed other autoimmune diseases (eg, ANCA-associated vasculitis,
             systemic lupus erythematosus, etc.)




18 Years - 70 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers


, 86-010-64456169, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Beijing Institute of Heart, Lung and Blood Vessel Diseases


 Shanghai Zhongshan Hospital

Study Sponsor

, , 

Verification Date

April 2022